|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's Range||16.50 - 18.45|
|52 Week Range||1.92 - 33.79|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were bouncing back somewhat on Friday after Thursday's sharp decline. It's also possible that some short-sellers could be covering their positions before the weekend as a precaution in case Inovio announces good news before Monday. There seems to be a good chance that Inovio will have positive news to announce in the near future.
Shares of the developmental vaccine and immunotherapy company Inovio Pharmaceuticals (NASDAQ: INO) fell by as much as 15.8% right out of the gate Thursday morning. Investors seemingly piled into this biotech stock this week in the hopes of getting in before the company lands a large grant for its COVID-19 vaccine candidate, INO-4800. Not everyone was impressed by Inovio's investor presentation, however.
Jared Holz, Healthcare Equity Strategist at Jefferies, weighs in on the latest coronavirus vaccine developments, as President Trump states in an interview that a COVID-19 vaccine may be ready in four weeks.